Page 1 | Search Results | Diabetes Care | American Diabetes Association

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128–2136

Geremia B. Bolli, Francesca Porcellati, Paola Lucidi, Carmine G. Fanelli

Diabetes Care 2021;44(3):e59–e60

https://doi.org/10.2337/dc20-2575

Published: 11 February 2021

View article titled, Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128–2136

Journal Articles

Pharmacokinetic and Pharmacodynamic Head-to-Head Comparison of Clinical, Equivalent Doses of Insulin Glargine 300 units · mL⁻¹ and Insulin Degludec 100 units · mL⁻¹ in Type 1 Diabetes

Paola Lucidi, Paola Candeloro, Patrizia Cioli, Anna Marinelli Andreoli, Chiara Pascucci, Angela Gambelunghe, Geremia B. Bolli, Carmine G. Fanelli, Francesca Porcellati

Diabetes Care 2021;44(1):125–132

https://doi.org/10.2337/dc20-1033

Published: 10 November 2020

View article titled, Pharmacokinetic and Pharmacodynamic Head-to-Head Comparison of Clinical, Equivalent Doses of Insulin Glargine 300 units · mL<sup>−1</sup> and Insulin Degludec 100 units · mL<sup>−1</sup> in Type 1 Diabetes

Journal Articles

Switching From Insulin Bolus Treatment to GLP-1 RAs Added to Continued Basal Insulin in People With Type 2 Diabetes on Basal-Bolus Insulin

Geremia B. Bolli, Francesca Porcellati, Juris J. Meier

Diabetes Care 2020;43(10):2333–2335

https://doi.org/10.2337/dci20-0038

Published: 11 September 2020

View article titled, Switching From Insulin Bolus Treatment to GLP-1 RAs Added to Continued Basal Insulin in People With Type 2 Diabetes on Basal-Bolus Insulin

Journal Articles

Erratum. A Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study. Diabetes Care 2018;41: 1672–1680

Robert Ritzel, Stewart B. Harris, Helen Baron, Hermes Florez, Ronan Roussel, Melanie Espinasse, Isabel Muehlen-Bartmer, Nianxian Zhang, Monica Bertolini, Claire Brulle-Wohlhueter, Medha Munshi, Geremia B. Bolli

Diabetes Care 2019;42(8):1604

https://doi.org/10.2337/dc19-er08

Published: 21 June 2019

View article titled, Erratum. A Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study. Diabetes Care 2018;41: 1672–1680

Journal Articles

Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes

Francesca Porcellati, Paola Lucidi, Paola Candeloro, Patrizia Cioli, Anna Marinelli Andreoli, Gianluca Curti, Geremia B. Bolli, Carmine G. Fanelli

Diabetes Care 2019;42(1):85–92

https://doi.org/10.2337/dc18-0706

Published: 10 October 2018

View article titled, Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes

Includes: Supplementary data

Journal Articles

John E. Gerich: Father of Modern Physiology of Glucose Homeostasis, Counterregulation to Hypoglycemia, and Mechanistic Treatment of Diabetes

Geremia B. Bolli

Diabetes Care 2018;41(10):2059–2063

https://doi.org/10.2337/dci18-0027

Published: 11 September 2018

View article titled, John E. Gerich: Father of Modern Physiology of Glucose Homeostasis, Counterregulation to Hypoglycemia, and Mechanistic Treatment of Diabetes

Journal Articles

More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial

Julio Rosenstock, Alice Cheng, Robert Ritzel, Zsolt Bosnyak, Christine Devisme, Anna M.G. Cali, Jochen Sieber, Peter Stella, Xiangling Wang, Juan P. Frías, Ronan Roussel, Geremia B. Bolli

Diabetes Care 2018;41(10):2147–2154

https://doi.org/10.2337/dc18-0559

Published: 13 August 2018

View article titled, More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial

Includes: Supplementary data

Journal Articles

A Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study

Diabetes Care 2018;41(8):1672–1680

https://doi.org/10.2337/dc18-0168

Published: 12 June 2018

View article titled, A Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study

Includes: Supplementary data

Journal Articles

How to Accurately Establish Pharmacokinetics/Pharmacodynamics of Long-Acting Insulins in Humans: Relevance to Biosimilar Insulins

Francesca Porcellati, Paola Lucidi, Geremia B. Bolli, Carmine G. Fanelli

Diabetes Care 2015;38(12):2237–2240

https://doi.org/10.2337/dc15-1848

Published: 19 November 2015

View article titled, How to Accurately Establish Pharmacokinetics/Pharmacodynamics of Long-Acting Insulins in Humans: Relevance to Biosimilar Insulins

Journal Articles

Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection

Paola Lucidi, Francesca Porcellati, Anna Marinelli Andreoli, Ilaria Carriero, Paola Candeloro, Patrizia Cioli, Geremia B. Bolli, Carmine G. Fanelli

Diabetes Care 2015;38(12):2204–2210

https://doi.org/10.2337/dc15-0801

Published: 10 September 2015

View article titled, Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection

Includes: Supplementary data

Journal Articles

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4)

Philip D. Home, Richard M. Bergenstal, Geremia B. Bolli, Monika Ziemen, Maria Rojeski, Melanie Espinasse, Matthew C. Riddle

Diabetes Care 2015;38(12):2217–2225

https://doi.org/10.2337/dc15-0249

Published: 17 June 2015

View article titled, New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4)

Includes: Supplementary data

Journal Articles

Low Levels of Unmodified Insulin Glargine in Plasma of People With Type 2 Diabetes Requiring High Doses of Basal Insulin

Paola Lucidi, Francesca Porcellati, Hannele Yki-Järvinen, Matthew C. Riddle, Paola Candeloro, Anna Marinelli Andreoli, Geremia B. Bolli, Carmine G. Fanelli

Diabetes Care 2015;38(7):e96–e97

https://doi.org/10.2337/dc14-2662

Published: 11 June 2015

View article titled, Low Levels of Unmodified Insulin Glargine in Plasma of People With Type 2 Diabetes Requiring High Doses of Basal Insulin

Journal Articles

New Long-Acting Insulin Analogs: From Clamp Studies to Clinical Practice

Geremia B. Bolli, J. Hans DeVries

Diabetes Care 2015;38(4):541–543

https://doi.org/10.2337/dc14-2314

Published: 14 March 2015

View article titled, New Long-Acting Insulin Analogs: From Clamp Studies to Clinical Practice

Journal Articles

Pharmacokinetics and Pharmacodynamics of Insulin Glargine Given in the Evening as Compared With in the Morning in Type 2 Diabetes

Francesca Porcellati, Paola Lucidi, Patrizia Cioli, Paola Candeloro, Anna Marinelli Andreoli, Stefania Marzotti, Maura Ambrogi, Geremia B. Bolli, Carmine G. Fanelli

Diabetes Care 2015;38(3):503–512

https://doi.org/10.2337/dc14-0649

Published: 18 December 2014

View article titled, Pharmacokinetics and Pharmacodynamics of Insulin Glargine Given in the Evening as Compared With in the Morning in Type 2 Diabetes

Includes: Supplementary data

Journal Articles

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)

Matthew C. Riddle, Geremia B. Bolli, Monika Ziemen, Isabel Muehlen-Bartmer, Florence Bizet, Philip D. Home

Diabetes Care 2014;37(10):2755–2762

https://doi.org/10.2337/dc14-0991

Published: 10 September 2014

View article titled, New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)

Includes: Supplementary data

Journal Articles

Thirty Years of Research on the Dawn Phenomenon: Lessons to Optimize Blood Glucose Control in Diabetes

Francesca Porcellati, MD, PHD, Paola Lucidi, MD, PHD, Geremia B. Bolli, MD, Carmine G. Fanelli, MD, PHD

Diabetes Care 2013;36(12):3860–3862

https://doi.org/10.2337/dc13-2088

Published: 13 November 2013

View article titled, Thirty Years of Research on the Dawn Phenomenon: Lessons to Optimize Blood Glucose Control in Diabetes

Journal Articles

The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: The T-emerge 2 trial

Julio Rosenstock, MD, Bogdan Balas, MD, Bernard Charbonnel, MD, Geremia B. Bolli, MD, Mark Boldrin, MS, Robert Ratner, MD, Raffaella Balena, MD, for the T-emerge 2 Study Group

Diabetes Care 2013;36(3):498–504

https://doi.org/10.2337/dc12-0709

Published: 13 February 2013

View article titled, The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: <subtitle>The T-emerge 2 trial</subtitle>

Includes: Supplementary data

Journal Articles

Plasma Exposure to Insulin Glargine and Its Metabolites M1 and M2 After Subcutaneous Injection of Therapeutic and Supratherapeutic Doses of Glargine in Subjects With Type 1 Diabetes

Geremia B. Bolli, MD, Annke D. Hahn, PHD, Ronald Schmidt, PHD, Tanja Eisenblaetter, PHD, Raphael Dahmen, MD, Tim Heise, MD, Reinhard H.A. Becker, MD

Diabetes Care 2012;35(12):2626–2630

https://doi.org/10.2337/dc12-0270

Published: 14 November 2012

View article titled, Plasma Exposure to Insulin Glargine and Its Metabolites M1 and M2 After Subcutaneous Injection of Therapeutic and Supratherapeutic Doses of Glargine in Subjects With Type 1 Diabetes

Includes: Supplementary data

Journal Articles

Metabolism of Insulin Glargine After Repeated Daily Subcutaneous Injections in Subjects With Type 2 Diabetes

Paola Lucidi, MD, Francesca Porcellati, MD, Paolo Rossetti, MD, Paola Candeloro, PHD, Anna Marinelli Andreoli, MD, Patrizia Cioli, RD, Annke Hahn, PHD, Ronald Schmidt, PHD, Geremia B. Bolli, MD, Carmine G. Fanelli, MD

Diabetes Care 2012;35(12):2647–2649

https://doi.org/10.2337/dc12-0271

Published: 14 November 2012

View article titled, Metabolism of Insulin Glargine After Repeated Daily Subcutaneous Injections in Subjects With Type 2 Diabetes

Includes: Supplementary data

Journal Articles

Differential Effects of Adiposity on Pharmacodynamics of Basal Insulins NPH, Glargine, and Detemir in Type 2 Diabetes Mellitus

Francesca Porcellati, MD, Paola Lucidi, MD, Paolo Rossetti, MD, Paola Candeloro, PHD, Anna Marinelli Andreoli, MD, Stefania Marzotti, MD, Patrizia Cioli, RD, Geremia B. Bolli, MD, Carmine G. Fanelli, MD

Diabetes Care 2011;34(12):2521–2523

https://doi.org/10.2337/dc11-1064

Published: 14 November 2011

View article titled, Differential Effects of Adiposity on Pharmacodynamics of Basal Insulins NPH, Glargine, and Detemir in Type 2 Diabetes Mellitus

Includes: Supplementary data

NARROW

Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128–2136

Pharmacokinetic and Pharmacodynamic Head-to-Head Comparison of Clinical, Equivalent Doses of Insulin Glargine 300 units · mL⁻¹ and Insulin Degludec 100 units · mL⁻¹ in Type 1 Diabetes

Switching From Insulin Bolus Treatment to GLP-1 RAs Added to Continued Basal Insulin in People With Type 2 Diabetes on Basal-Bolus Insulin

Erratum. A Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study. Diabetes Care 2018;41: 1672–1680

Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes

John E. Gerich: Father of Modern Physiology of Glucose Homeostasis, Counterregulation to Hypoglycemia, and Mechanistic Treatment of Diabetes

More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial

A Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study

How to Accurately Establish Pharmacokinetics/Pharmacodynamics of Long-Acting Insulins in Humans: Relevance to Biosimilar Insulins

Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4)

Low Levels of Unmodified Insulin Glargine in Plasma of People With Type 2 Diabetes Requiring High Doses of Basal Insulin

New Long-Acting Insulin Analogs: From Clamp Studies to Clinical Practice

Pharmacokinetics and Pharmacodynamics of Insulin Glargine Given in the Evening as Compared With in the Morning in Type 2 Diabetes

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)

Thirty Years of Research on the Dawn Phenomenon: Lessons to Optimize Blood Glucose Control in Diabetes

The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: The T-emerge 2 trial

Plasma Exposure to Insulin Glargine and Its Metabolites M1 and M2 After Subcutaneous Injection of Therapeutic and Supratherapeutic Doses of Glargine in Subjects With Type 1 Diabetes

Metabolism of Insulin Glargine After Repeated Daily Subcutaneous Injections in Subjects With Type 2 Diabetes

Differential Effects of Adiposity on Pharmacodynamics of Basal Insulins NPH, Glargine, and Detemir in Type 2 Diabetes Mellitus

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

This Feature Is Available To Subscribers Only